浙江英特集团股份有限公司 2024 年度独立董事述职报告 2024年，本人黄英严格按照《公司法》《证券法》等法律法规，以及浙江英特集团股份 有限公司《公司章程》和《独立董事制度》等有关规定和要求，本着客观、公正、独立的原 则，勤勉尽责、独立履职，及时了解公司的生产经营及发展情况，准时出席相关会议，积极 发挥独立董事作用，有效维护了公司整体利益和全体股东的合法权益。现将独立董事年度履 职情况报告如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 黄英 教授、博士生导师。曾任浙江大学财务与会计学系系主任。现任 浙江大学管理 学院教授、会计学和金融学博士生导师，浙江大学资本市场研究中心主任，本公司独立董事。 报告期内，本人任董事会审计委员会主任委员、薪酬与考核委员会委员。 （二）不存在影响独立性的情况 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第1号— 主板上市公司规范运作》等相关规定，本人作为公司独立董事，对自身独立性情况进行了自 查。2024年度，本人未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍本 ...

浙江英特集团股份有限公司 2024 年度独立董事述职报告 2024年任职期间，本人李耀严格按照《公司法》《证券法》等法律法规，以及浙江英特 集团股份有限公司《公司章程》和《独立董事制度》等有关规定和要求，本着客观、公正、 独立的原则，勤勉尽责、独立履职，及时了解公司的生产经营及发展情况，准时出席相关会 议，积极发挥独立董事作用，有效维护了公司整体利益和全体股东的合法权益。现将独立董 事年度履职情况报告如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 李耀 上海中医药大学客座教授、中欧国际工商学院MBA导师。曾任北京化工研究院计 算机中心助理工程师，美国麦道飞机（中国）公司补偿贸易专家，雀巢中国有限公司营销经 理，英国葛兰丹宁管理咨询公司咨询总监，葛兰素史克中美史克制药有限公司全国销售总监， Kappa体育用品有限公司营销副总裁，知蜂堂产品有限公司总经理，西安杨森制药有限公司 副总裁，中康科技副总裁，北京中康瑞马营销科技有限公司联合创始人兼CEO。现任中国非 处方药协会市场营销专委会主任，中国品牌建设促进会OTC品牌集群常务副秘书长，本公司 独立董事，成都市贝瑞和康基因技术股份有限公司独立董事。 报告 ...

浙江英特集团股份有限公司 2024 年度独立董事述职报告 2024年，本人余军严格按照《公司法》《证券法》等法律法规，以及浙江英特集团股份 有限公司《公司章程》和《独立董事制度》等有关规定和要求，本着客观、公正、独立的原 则，勤勉尽责、独立履职，及时了解公司的生产经营及发展情况，准时出席相关会议，积极 发挥独立董事作用，有效维护了公司整体利益和全体股东的合法权益。现将独立董事年度履 职情况报告如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 余军 教授、博士生导师。曾任华南理工大学法学院教授、博士生导师，浙江工业大学 法学院副教授、硕士生导师、学科负责人。现任浙江大学光华法学院教授、博士生导师，浙 江立法研究院暨浙江大学立法研究院常务副院长，本公司、浙江浙能迈领环境科技股份有限 公司独立董事。 报告期内，本人任董事会提名委员会主任委员、审计委员会委员。 （二）不存在影响独立性的情况 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第1号— 主板上市公司规范运作》等相关规定，本人作为公司独立董事，对自身独立性情况进行了自 查。2024年度，本人未在公司担任除独立董事以外的任何职务， ...

根据中国证券监督管理委员会《上市公司独立董事管理办法》《深圳证券交易所股票上 市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等要 求，浙江英特集团股份有限公司（以下简称"公司"） 董事会，就公司在任独立董事黄英、 陈昊、余军、李耀的独立性情况进行评估并出具如下专项意见： 经核查独立董事黄英、陈昊、余军、李耀的任职经历以及签署的相关自查文件，上述人 员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任何职务，与公 司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不存在影 响独立董事独立性的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 浙江英特集团股份有限公司董事会 关于独立董事独立性自查情况的专项报告 浙江英特集团股份有限公司董事会 2025 年 4 月 25 日 ...

浙江英特集团股份有限公司 2024 年度独立董事述职报告 2024年，本人陈昊严格按照《公司法》《证券法》等法律法规，以及浙江英特集团股份 有限公司《公司章程》和《独立董事制度》等有关规定和要求，本着客观、公正、独立的原 则，勤勉尽责、独立履职，及时了解公司的生产经营及发展情况，准时出席相关会议，积极 发挥独立董事作用，有效维护了公司整体利益和全体股东的合法权益。现将独立董事年度履 职情况报告如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 陈昊 高级经济师。曾任 广东省中山市卫生局、广东省卫生厅药政处职员，美国礼来 亚洲公司广州办事处地区经理，医学与社会编辑部主任。现任 华中科技大学同济医学院药 品政策与管理研究中心主任，同济医学院教师、研究员，武汉大学全球健康研究中心教授， 本公司独立董事。 2024年1月1日至8月14日，本人任董事会薪酬与考核委员会主任委员，提名委员会、战 略委员会委员。2024年8月15日至12月31日，本人任董事会薪酬与考核委员会主任委员、提 名委员会委员。 （二）不存在影响独立性的情况 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第1号— 主板上 ...

Financial Performance - The company's operating revenue for 2024 reached ¥33,351,653,828.95, representing a 4.05% increase compared to ¥32,052,121,586.44 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥525,522,107.14, a 7.53% increase from ¥488,732,096.82 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥509,880,346.81, which is a 25.74% increase from ¥405,498,097.75 in 2023[20]. - The total assets at the end of 2024 amounted to ¥14,632,477,002.42, reflecting a 5.20% increase from ¥13,908,856,860.12 at the end of 2023[20]. - The company's basic earnings per share for 2024 was ¥1.02, down 6.42% from ¥1.09 in 2023[20]. - The company reported a cash flow from operating activities net amount of ¥410,324,781.82, a decrease of 3.52% compared to ¥425,313,727.37 in 2023[20]. - The company achieved a gross margin of 6.63% in pharmaceutical sales, with a slight increase of 0.25% year-on-year[65]. - The total operating revenue for 2024 reached ¥33.35 billion, representing a 4.05% increase from ¥32.05 billion in 2023[64]. - The pharmaceutical wholesale sector accounted for ¥29.93 billion, or 89.75% of total revenue, with a year-on-year growth of 2.90%[65]. - The pharmaceutical retail sector saw a significant increase of 15.46%, generating ¥3.18 billion, which is 9.53% of total revenue[64]. Dividends and Shareholder Engagement - The company plans to distribute a total cash dividend of 200 million CNY to all shareholders, with no stock dividends issued[4]. - The company implemented a stable cash dividend policy, with a cash dividend of 200 million yuan (including tax), representing 38.06% of the net profit attributable to shareholders[165]. - The cash dividend per 10 shares is set at 3.83 yuan (including tax), based on a total share capital of 521,892,509 shares[165]. - The total cash dividend amount, including other methods, is 200 million yuan, which accounts for 100% of the total profit distribution[165]. - The company ensures that minority shareholders have sufficient opportunities to express their opinions and that their legal rights are fully protected[164]. - The participation ratio for the 2024 first extraordinary shareholders' meeting was 73.16%[130]. - The participation ratio for the 2023 annual shareholders' meeting was 73.14%[130]. - The participation ratio for the 2024 second extraordinary shareholders' meeting was 73.26%[130]. Corporate Governance and Management - The financial report is guaranteed to be true, accurate, and complete by the company's board and management[4]. - The company has a strong leadership team with members having backgrounds in finance, law, and strategic management, enhancing its operational capabilities[137]. - The company emphasizes compliance and legal oversight, with dedicated roles for legal and risk management within its executive team[141]. - The company has appointed independent directors with significant academic and industry experience, contributing to its governance and strategic direction[139]. - The board of directors held a total of 13 meetings during the reporting period, with all resolutions reported to the Shenzhen Stock Exchange[147]. - The independent directors provided valuable professional advice on internal control, management system construction, and major decision-making[152]. - The company has established a robust incentive mechanism for senior management, aligning their performance with company goals[169]. - The management team is evaluated based on performance metrics directly linked to their compensation, promoting accountability and performance improvement[169]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements related to development strategies and future plans[4]. - The company is committed to maintaining high standards in quality and compliance, as indicated by the roles of its quality management team[135]. - The company adheres to strict quality management protocols to mitigate risks associated with product quality issues, which could lead to financial and reputational damage[119]. - The company is focused on enhancing its governance structure and talent acquisition strategies to optimize its workforce and improve operational efficiency[114]. - The company is committed to fulfilling all promises made during the acquisition process, with accountability for any breaches[185]. - The company will ensure compliance with relevant laws and regulations regarding related transaction decision-making procedures and information disclosure obligations[187]. Strategic Development and Market Position - The company is positioned in the pharmaceutical distribution industry, which is undergoing modernization and digital transformation, driven by increasing consumer demand and regulatory reforms[29]. - The company aims to enhance its market share in pharmaceuticals and expand its professional marketing efforts, targeting a leading position in every market segment within the province[111]. - The company plans to accelerate mergers and acquisitions, focusing on top-ranked pharmaceutical wholesale enterprises with a scale of over several billion in economically developed regions[115]. - The company is advancing its digital transformation, aiming to fully utilize data in its operations and enhance organizational efficiency[60]. - The company is focusing on high-value-added areas and exploring partnerships with commercial insurance to broaden payment channels and enhance customer service[118]. Community Engagement and Social Responsibility - The company is committed to social responsibility and sustainable development, aiming to create value for shareholders while contributing positively to society[111]. - The company donated 300,000 yuan to support sustainable development in rural areas, contributing to poverty alleviation efforts[181]. - The company has actively engaged in over 30 volunteer activities, involving 563 participants, to promote social responsibility and community support[180]. - The company is involved in strategic partnerships to enhance its service offerings and community impact[182]. Investments and Acquisitions - The company acquired 51% of Shenzhou Yintianhua Pharmacy and 100% of Hangzhou Guangji Huanlong Trading Co., expanding its market presence[70]. - The company has established a comprehensive provincial distribution network with six logistics centers and over 200 retail stores across 11 cities in Zhejiang province[40][42]. - The company initiated the construction of the Zhejiang Yinte Shitang Pharmaceutical Industrial Park, covering an area of 119 acres, to enhance logistics and industry incubation[59]. - The company is developing an end-to-end cold chain logistics system for vaccines, aiming for real-time monitoring and precise regulation[74]. Digital Transformation and Technology - The company is advancing its digital transformation to improve logistics efficiency and service quality through a comprehensive information management system[49]. - The government is promoting digital transformation in the pharmaceutical industry, emphasizing the integration of AI and big data technologies[34]. - The company has developed a digital energy monitoring platform to automate energy consumption data collection and analysis, enhancing operational efficiency[177]. Employee Management and Development - The total number of employees at the end of the reporting period is 3,072, with 1,695 in sales and 165 in finance[158]. - The company has established a training plan to enhance the skills of its workforce, focusing on high-quality talent development[161]. - The company has implemented a salary policy that links compensation to performance and strategic business support[160]. Financial Management and Internal Controls - The company has implemented an effective internal control system, ensuring compliance with laws and regulations, and enhancing operational efficiency[170]. - The internal control measures have met the expected objectives, safeguarding the interests of the company and its shareholders[170]. - The company maintained effective internal control over financial reporting as of December 31, 2024, according to the internal control audit report[174].

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-012 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 2025 年第一季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 英特转债（债券代码：127028）转股期为 2021 年 7 月 12 日至 2027 年 1 月 4 日，截 至目前，转股价格为人民币 9.68 元/股。 根据《深圳证券交易所股票上市规则》《深圳证券交易所可转换公司债券业务实施细则》 的有关规定，浙江英特集团股份有限公司（以下简称"英特集团"或"公司"）现将 2025 年第 一季度可转换公司债券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债发行上市基本情况 2022 年 9 月 21 日，公司召开九届二十次董事会议、九届十三次监事会议，审议通过了 《关于调整 2021 年限制性股票激励计划预留授予数量的议案》《关于向激励对象授予预留 部分限制性股票的议案》，鉴于公司已完成 ...

因公司本次回购注销部分限制性股票占公司总股本比例较小，经计算，"英特转债"的 转股价格不做调整。目前"英特转债"的转股价格为 9.68 元/股。 | 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-011 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 关于回购注销部分限制性股票不调整"英特转债"转股价 格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 经中国证券监督管理委员会《关于核准浙江英特集团股份有限公司公开发行可转换公司 债券的批复》（证监许可[2020]3159 号）核准，同意浙江英特集团股份有限公司（以下简称 "公司"）向社会公开发行面值总额 6 亿元可转换公司债券，期限 6 年。经深圳证券交易所 同意，公司可转换公司债券自 2021 年 3 月 10 日起在深交所上市交易，债券简称为"英特转 债"，债券代码为"127028"。 根据《浙江英特集团股份有限公司公开发行可转换公司债 ...

| 证券代码：000411 | 证券简称：英特集团 公告编号：2025-010 | | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | 浙江英特集团股份有限公司 关于 2021 年限制性股票激励计划 部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、浙江英特集团股份有限公司（以下简称"公司"）2021 年限制性股票激励计划 （以下简称"本激励计划"）本次回购注销的限制性股票数量为 259,440 股，占回购注 销前公司总股本的 0.05%。本次回购注销涉及首次授予 12 名激励对象，回购价格为 4.47 元/股，预留授予 3 名激励对象，回购价格为 4.87 元/股。本次回购注销完成后， 公司股份总数由 522,151,743 股减少至 521,892,303 股。 2、截至 2025 年 3 月 10 日，上述限制性股票已在中国证券登记结算有限责任公 司深圳分公司办理完成注销手续。 3、因本次回购注销股份占公司总股本比例较小，经计算，"英特转债"的转股价 格不作调整，转股价格 ...

Core Viewpoint - The recent leadership changes at Yingte Group, including the resignation of Chairman Ying Xueqi and the election of Wang Yang as the new chairman, are part of normal personnel adjustments within the company [1][3]. Company Overview - Yingte Group is a large regional pharmaceutical distribution enterprise in China, involved in various sectors including pharmaceuticals, medical devices, new retail, logistics, and traditional Chinese medicine, with a significant sales network in East China, particularly Zhejiang [2]. - The company is controlled by Zhejiang Provincial State-owned Assets Supervision and Administration Commission and has undergone several ownership changes since its establishment in 1950 [2][3]. Leadership Changes - Ying Xueqi has resigned from all positions within Yingte Group, while Wang Yang has been elected as the new chairman, with his term lasting until the current board's term ends [1][3]. - Ying Xueqi has a long tenure with the company, having joined in 1995, while Wang Yang has held various leadership roles within the organization [3][4]. Financial Performance - Yingte Group's revenue has grown significantly, surpassing 300 billion yuan, with annual revenues from 2018 to 2023 reported as follows: 204.92 billion, 246.01 billion, 250.08 billion, 267.31 billion, 306.19 billion, and 320.52 billion yuan [5]. - The company's profitability remains relatively weak, with gross and net profit margins consistently around 6%-6.8% and 1%-1.8% respectively since 2018 [5]. - For the first three quarters of 2024, Yingte Group reported a revenue of 247.77 billion yuan, a year-on-year increase of 3.59%, and a non-recurring net profit of 3.4 billion yuan, up 24.54% year-on-year [5].